ClinicalTrials.gg
Active, not recruitingNCT05478551Updated Jan 15, 2026

Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization

A Phase 2/3 interventional study of Botulinum Toxin and Normal saline in Scar and Hypertrophic Scar, sponsored by Henry Ford Health System. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.

Primary conditionCicatrix, HypertrophicRegistry: CicatrixReclassifiedWhy we changed it
Registry
Cicatrix — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cicatrix, Hypertrophic
Why
  1. The study's listed conditions name Cicatrix, Hypertrophic, a narrower term within Cicatrix.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Henry Ford Health System · Phase 2/3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Cicatrix, Hypertrophic with a site in United States — 7 open to participants now, 8 under way, 2 of them phase 3. Cicatrix, Hypertrophic · United States.

Enrollment
26th of 35
12 · median 22
Started
2022
with 2 others
Phase 2/3
2 of 38
none open now
Registered
33rd of 38
by date
Lead sponsor
2 of 38
Henry Ford Health System

Among the 38 studies in Cicatrix, Hypertrophic with a site in United States, this one is the 26th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2022, is one of 2 in phase 2/3, and was the 33rd registered.

Cicatrix, Hypertrophic

129 studies on the registry are indexed under Cicatrix, Hypertrophic; 31 are open to participants now.

Browse Cicatrix, Hypertrophic studies →

Open to participants now

7 of the 38 studies in Cicatrix, Hypertrophic with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Cicatrix, Hypertrophic studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Cicatrix, Hypertrophic with a site in United States, or all of them as a file.
02

Study summary

The proposed study seeks to evaluate the scar reduction capacity of BTA on excision/biopsy wounds compared to the control (normal saline) in a double-blinded randomized control trial. It will expand upon previous studies that have already demonstrated the safety and good tolerance profile of BTA. We will be conducting a split-scar study/study involving two biopsy sites in a singular patient, allowing them to serve as their own control. In keeping with the results from previously conducted studies, we hypothesize that the wounds treated with BTA will have significantly less evidence of scar formation than those sites treated with normal saline.

Read the detailed description

The process of scar formation is denoted by three stages: inflammatory, proliferative, and remodeling. The former phase is characterized by the activation of the extrinsic clotting pathway and subsequent materialization of a fibrin plug, after which neutrophils facilitate the degradation of pathogens and secretion of signaling molecules that commence the proliferative phase. The fibrin plug is then replaced by granulation tissue comprised of macrophages, fibroblast, and endothelial cells in the proliferative phase. Through the release several growth factors, existing macrophages induce laying down of type III collagen by fibroblasts, and keratinocytes work in tandem to approximate wound edges. Lastly, during the remodeling phase, cellular apoptosis causes granulation tissue formation to subside, type III collagen is replaced by a more durable collagen type I, and myofibroblasts help to condense the scar size.1,2

While scarring in its non-pathological forms is an innate and appropriate bodily response to cutaneous injury, scar development and persistence can have negative physical and psychological implications, including decreased range of motion secondary to contracture, disfigurement, and impaired quality of life.1,3-5 Thus, for medical and cosmetic purposes alike, curtailing scar formation is important aspect of patient management, and treatment aimed at both prevention and resolution is an evolving subject in the medical discourse. Credence has been given to the use of botulinum toxin A (BTA) in scar minimization, a more novel therapy, and has proved efficacious in several studies including those examining BTA in the treatment of keloids and hypertrophic scars, mammoplasty and abdominoplasty surgery scars, and post-operative scars generally.6-9 The suggested mechanisms for this phenomenon involve inhibition of pre-synaptic acetylcholine channels that lead to muscle paralysis and relaxation of perpendicular wound tension; this particular mechanism is likewise theorized to mitigate collagen overproduction. Another hypothesis for explaining the ability of BTA to reduce scar appearance is the direct modulation of fibroblast activity.6

03

Conditions studied

  • Scar
  • Hypertrophic Scar

Browse trials for

Keywords

  • botulinum toxin
  • scar prevention
  • scar formation
04

In context

Cicatrix, Hypertrophic Reclassified

129 studies on the registry are indexed under Cicatrix, Hypertrophic; 31 are open to participants now.

This study's enrollment of 12 is below the median of 36 across 106 interventional studies indexed under Cicatrix, Hypertrophic.

Browse Cicatrix, Hypertrophic studies →

Lead sponsor

Henry Ford Health System is the lead sponsor of 304 studies on the registry; 51 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 26 (70%) have results posted.

Compared within Cicatrix, Hypertrophic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cicatrix. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Individuals age 18 and older
  • Able to understand the requirements of the study and its associated risks
  • Able to complete and sign a consent form

Exclusion criteria

Exclusion Criteria:

  • Allergy to botulinum toxin
  • Currently pregnant or breastfeeding
  • Myasthenia gravis
  • Previous injection of botulinum toxin in the specified treatment areas within 6 months prior to enrollment
  • Unable to follow up 6 months after procedure
  • Refusal to participate in the trial
  • History of keloid or hypertrophic scars
  • Eaton-Lambert Syndrome
  • Amyopathic Lateral Sclerosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Botulinum toxin

    Biopsy site receiving botulinum toxin Following the biopsy closures, one of two biopsy sites (left or right) will be selected to receive 30u (0.3cc) of botulinum toxin injected into the suture line at a depth of PPD bleb. The treatment for each wound site will be randomized (left versus right) and blinded but consistent throughout dosing.

    Drug: Botulinum Toxin

  • Placebo comparator
    Placebo

    Placebo Comparator: Biopsy site receiving placebo Following the biopsy closures, the other biopsy site will receive 30u (0.3cc) of bacteriostatic normal saline injected into the suture line at a depth of PPD bleb.

    Drug: Normal saline

Interventions

  • DrugBotulinum ToxinsStudies of Botulinum ToxinsBotulinum Toxins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    We will be comparing botulinum toxin following the biopsies to placebo injection. We will then compare photos of each biopsy site at set intervals following the procedure.

    Also known as: Dysport, BTXa, abobotulinumtoxinA

  • DrugNormal saline

    Normal saline will serve as the placebo control on the contralateral side of the back.

    Also known as: Placebo

07

What researchers measure

Primary outcomes

  1. Primary Outcome Measure

    Modified Patient and Observer Scar Assessment Scale v2.0 (POSAS)

    Time frame: 3 months

  2. Primary Outcome Measure

    Modified Patient and Observer Scar Assessment Scale v2.0 (POSAS)

    Time frame: 6 months

08

Study locations

1 site
09

References and documents

Publications

  • Tziotzios C, Profyris C, Sterling J. Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics Part II. Strategies to reduce scar formation after dermatologic procedures. J Am Acad Dermatol. 2012 Jan;66(1):13-24; quiz 25-6. doi: 10.1016/j.jaad.2011.08.035. PubMed 22177632 ↗
  • Kasyanju Carrero LM, Ma WW, Liu HF, Yin XF, Zhou BR. Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: Updated review. J Cosmet Dermatol. 2019 Feb;18(1):10-15. doi: 10.1111/jocd.12828. Epub 2018 Dec 12. PubMed 30548742 ↗
  • Oosterwijk AM, Mouton LJ, Schouten H, Disseldorp LM, van der Schans CP, Nieuwenhuis MK. Prevalence of scar contractures after burn: A systematic review. Burns. 2017 Feb;43(1):41-49. doi: 10.1016/j.burns.2016.08.002. Epub 2016 Sep 14. PubMed 27639820 ↗
  • Oh H, Boo S. Assessment of burn-specific health-related quality of life and patient scar status following burn. Burns. 2017 Nov;43(7):1479-1485. doi: 10.1016/j.burns.2017.03.023. Epub 2017 May 21. PubMed 28539239 ↗
  • Ziolkowski N, Kitto SC, Jeong D, Zuccaro J, Adams-Webber T, Miroshnychenko A, Fish JS. Psychosocial and quality of life impact of scars in the surgical, traumatic and burn populations: a scoping review protocol. BMJ Open. 2019 Jun 3;9(6):e021289. doi: 10.1136/bmjopen-2017-021289. PubMed 31164358 ↗
  • Abedini R, Mehdizade Rayeni N, Haddady Abianeh S, Rahmati J, Teymourpour A, Nasimi M. Botulinum Toxin Type A Injection for Mammoplasty and Abdominoplasty Scar Management: A Split-Scar Double-Blinded Randomized Controlled Study. Aesthetic Plast Surg. 2020 Dec;44(6):2270-2276. doi: 10.1007/s00266-020-01916-7. Epub 2020 Aug 19. PubMed 32813130 ↗
  • Yang W, Li G. The Safety and efficacy of botulinum toxin type A injection for postoperative scar prevention: A systematic review and meta-analysis. J Cosmet Dermatol. 2020 Apr;19(4):799-808. doi: 10.1111/jocd.13139. Epub 2019 Sep 12. PubMed 31513335 ↗
  • Guo X, Song G, Zhang D, Jin X. Efficacy of Botulinum Toxin Type A in Improving Scar Quality and Wound Healing: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Aesthet Surg J. 2020 Apr 14;40(5):NP273-NP285. doi: 10.1093/asj/sjz165. PubMed 31155638 ↗

Individual participant data

Plan to share: No — There will be a publication based on the results of the study. We will not be sharing individual participant data outside of our institution and all data collected will be kept on a secured drive within the Henry Ford Health System.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2022
First posted
Jul 28, 2022
StartActual
Jun 1, 2022
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05478551
Responsible party
David M. Ozog (Department Chair, Henry Ford Health System) — Principal investigator
First posted
Jul 28, 2022
Start date
Jun 1, 2022
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jan 15, 2026

Study contacts

David Ozog, MD
principal investigator · Henry Ford Health Systems

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum Toxins

Start the discussion